Tislelizumab plus chemotherapy (chemo) versus placebo plus chemo as first-line treatment for locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: RATIONALE-305 European/North American patient subgroup.

Hendrik-Tobias  Arkenau

No Relationships to Disclose

Josep  Tabernero

Stock and Other Ownership Interests  - 1TRIALSP; Alentis Therapeutics; Oniria Therapeutics; Pangaea Oncology

Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Cardiff Oncology; CARsgen Therapeutics; Chugai Pharma; Daiichi Sankyo; F. Hoffmann LaRoche; Genentech; hC Bioscience Inc; Ikena Oncology; Inspirna; Lilly; Menarini; Merck Serono; Merus; Mirati Therapeutics; MSD; Neophore; Novartis; Ona Therapeutics; Orion Biotechnology; Peptomyc; Pfizer; Pierre Fabre; Samsung Bioepis; Sanofi; Scandion Oncology; Scorpion Therapeutics; Seagen; Servier; Sotio; Taiho Pharmaceutical; Takeda Pharmaceuticals International AG; Tolremo

Other Relationship - Imedex/HMP; Medscape; Peerview; Physicans' Education Resource

Marcia  Cruz-Correa

No Relationships to Disclose

Anastasia V.  Zimina

No Relationships to Disclose

Elena  Poddubskaya

No Relationships to Disclose

Fedor Vladimirovich  Moiseenko

Honoraria - AstraZeneca; BIOCAD; Pfizer; Roche

Consulting or Advisory Role - Pfizer

Travel, Accommodations, Expenses - AstraZeneca; R-Pharm; Roche

David R.  Spigel

Leadership - ASCO (Inst)

Consulting or Advisory Role - Abbvie (Inst); AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Jazz Pharmaceuticals (Inst); Lilly (Inst); Lyell Immunopharma (Inst); Molecular Templates (Inst); Monte Rosa Therapeutics (Inst); Novartis (Inst); Novocure (Inst); Regeneron (Inst); Sanofi/Aventis (Inst)

Research Funding - Abbvie (Inst); Aeglea Biotherapeutics (Inst); Agios (Inst); Amgen (Inst); Anheart Therapeutics (Inst); Apollomics (Inst); Arcus Biosciences (Inst); Arrys Therapeutics (Inst); Ascendis Pharma (Inst); Asher Biotherapeutics (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); BIND Therapeutics (Inst); BioNTech (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celgene (Inst); Celldex (Inst); Clovis Oncology (Inst); cyteir (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Elevation Oncology (Inst); Endeavor BioMedicines (Inst); Erasca, Inc (Inst); Faeth Therapeutics (Inst); Fujifilm (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); GRAIL (Inst); Hutchison MediPharma (Inst); ImClone Systems (Inst); Incyte (Inst); Ipsen (Inst); Janssen Oncology (Inst); Jazz Pharmaceuticals (Inst); Kronos Bio (Inst); Lilly (Inst); Loxo (Inst); Lyell Immunopharma (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Millennium (Inst); Moderna Therapeutics (Inst); Molecular Templates (Inst); Monte Rosa Therapeutics (Inst); Nektar (Inst); Neon Therapeutics (Inst); Novartis (Inst); Novocure (Inst); Peloton Therapeutics (Inst); PureTech (Inst); Razor Genomics (Inst); Repare Therapeutics (Inst); Rgenix (Inst); Shenzhen Chipscreen Biosciences (Inst); Stemline Therapeutics (Inst); Strata Oncology (Inst); Synthekine (Inst); Taiho Oncology (Inst); Tango Therapeutics (Inst); Tarveda Therapeutics (Inst); Tesaro (Inst); Tizona Therapeutics, Inc. (Inst); Transgene (Inst); University of Texas Southwestern Medical Center - Simmons Cancer Center (Inst); Verastem (Inst); Zai Lab (Inst)

Travel, Accommodations, Expenses - AstraZeneca; Genentech; Novartis

Lucjan S.  Wyrwicz

Honoraria - BeiGene; BMS; MSD

Consulting or Advisory Role - GlaxoSmithKline; SERVIER

Speakers' Bureau - BMS

Travel, Accommodations, Expenses - SERVIER

Umut  Disel

No Relationships to Disclose

Roberto  Pazo Cid

Consulting or Advisory Role - Astellas Pharma; AstraZeneca Spain; Bristol-Myers Squibb/Celgene; Eisai Europe; Ipsen; Roche; SERVIER

Speakers' Bureau - Astellas Pharma; AstraZeneca Spain; BMS GmbH & Co. KG; SERVIER

Travel, Accommodations, Expenses - BMS GmbH & Co. KG; Lilly

Antonio  Cubillo Gracian

No Relationships to Disclose

Inmaculada  Alés Diaz

Consulting or Advisory Role - AstraZeneca; Lilly; Merck

Lorenzo  Fornaro

Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Incyte; Lilly; MSD; SERVIER; Taiho Pharmaceutical

Speakers' Bureau - Bristol-Myers Squibb; Incyte; Lilly

Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Incyte (Inst); MSD (Inst); Roche (Inst)

Ludovic  Evesque

Honoraria - AstraZeneca; SERVIER

Yaling  Xu

Employment - BeiGene

Stock and Other Ownership Interests  - BeiGene

Tao  Sheng

Employment - BeiGene

Stock and Other Ownership Interests  - BeiGene

Silu  Yang

Employment - BeiGene

Stock and Other Ownership Interests  - BeiGene

Liyun  Li

Employment - BeiGene Beijing

Stock and Other Ownership Interests  - BeiGene Beijing

Travel, Accommodations, Expenses - BeiGene Beijing

Markus H.  Moehler

Honoraria - Amgen; Astellas Pharma; AstraZeneca/MedImmune; Bayer Schering Pharma; Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; Idience; Merck Serono; MSD Oncology; Pierre Fabre; Roche/Genentech; Sanofi; Servier; Transcenta; Triptych Health Partners

Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; BeiGene; BMS; Daiichi Sankyo Europe GmbH; Lilly; Merck Serono; MSD; Nordic Group; SERVIER; Taiho Pharmaceutical

Research Funding - Amgen (Inst); AstraZeneca (Inst); Leap Therapeutics (Inst); Merck Serono (Inst); MSD (Inst); Taiho Pharmaceutical (Inst)

Travel, Accommodations, Expenses - Amgen; ASCO; Bayer; BeiGene; ESMO; German Cancer Society; Merck Serono; MSD; Roche; Sanofi Pasteur

Rui-Hua  Xu

Consulting or Advisory Role - Astellas Pharma; AstraZeneca; BeiGene; Bristol-Myers Squibb; HenRui; Junshi Biosciences; KYM Biosciences; Merck Serono; Roche